在严重的COVID-19中评估伊马替尼:系统性审查和元分析
João Pedro Sarcinelli Chagas1, Juliana Ribeiro de Oliveira1, Vinicius Andreata Brandão1
1Centro de Ciências da Saúde, Curso de Medicina.
Transactions of the Royal Society of Tropical Medicine and Hygiene
|November 26, 2024
概括
伊马替尼不显著降低死亡率或改善严重疾病COVID-19患者的结果. 需要进一步的随机对照试验来充分评估伊马替尼布.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 临界护理医学 临界护理医学
背景情况:
- 对于严重的COVID-19来说,有限的治疗选择需要探索新的治疗剂.
- 伊马替尼的已知抗病毒和免疫调节特性表明,它在治疗严重的2019年新冠肺炎疾病 (COVID-19) 中具有潜在的实用性.
研究的目的:
- 系统地审查和元分析伊马替尼在治疗重病COVID-19患者中的疗效和安全性.
- 为了确定伊马替尼布是否为严重的COVID-19提供比标准护理或安慰剂更好的好处.
主要方法:
- 在Medline,Embase和Cochrane数据库中进行了全面的文献搜索,截至2023年11月.
- 包括的研究是随机对照试验 (RCT),评估伊马替尼对COVID-19的评估.
- 包含的RCT的偏差评估是使用Cochrane协作工具进行的.
主要成果:
- 分析了3项涉及561名参与者的RCT (276名伊马替尼,285名安慰剂).
- 在imaatinib和安慰剂组之间没有观察到统计学上显著的死亡率差异 (RR 0.61;95% CI 0.37至1.01;p=0.06).
- 与安慰剂相比,伊马替尼布治疗没有显著影响住院时间或严重不良事件的发生.
结论:
- 目前的证据不支持使用imaatinib治疗严重的COVID-19.
- 需要进一步进行严格的随机对照试验,以最终评估伊马替尼在住院COVID-19患者中的潜在作用.
更多相关视频
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
8.6K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
440
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...